Glucose in Dialysis Water in Diabetics With Chronic Renal Failure

This study has been completed.
Sponsor:
Information provided by:
Regional Hospital Holstebro
ClinicalTrials.gov Identifier:
NCT00438503
First received: February 20, 2007
Last updated: September 14, 2007
Last verified: September 2007
  Purpose

The purposes are 1. to measure the effect of dialysis with glucose in dialysis water on blood pressure, pulse rate, plasma concentration of glucose, plasma concentrations og insulin, glucagon, growth hormone, renin, angiotensin II, endothelin and body temperature, and 2. to analyse the relationship between the changes in blood pressure and changes in vasoactive hormones


Condition Intervention Phase
Renal Failure, Chronic
Diabetic Nephropathies
Procedure: Procedure
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Glucose in Dialysis Water in Diabetics With Chronic Renal Failure on Blood Pressure, Pulse Rate, Plasma Glucose, Plasma Concentrations of Insulin, Growth Hormone, Renin, Angiotensin II, Endothelin and Body Temperature

Resource links provided by NLM:


Further study details as provided by Regional Hospital Holstebro:

Primary Outcome Measures:
  • Effect og glucose in dialysis water on blood pressure, plasma glucose and hormones in plasma

Secondary Outcome Measures:
  • Relationship between changes in blood pressure and and changes in hormones

Enrollment: 18
Study Start Date: May 2006
Study Completion Date: May 2007
Detailed Description:

The relationship between blood pressure during dialysis treatment and vasoactive hormones are studied. This includes measurements of plasma concentration of glucose, plasma concentrations og insulin, glucagon, growth hormone, renin, angiotensin II, endothelin

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age > 18 years,
  2. Both men and women,
  3. Dialysis treatment for at least three month due to diabetic nephropathy

Exclusion Criteria:

  1. Heart failure,
  2. Lung insufficiency,
  3. Chronic liver disease,
  4. Malignant disease,
  5. Nephrotic syndrome,
  6. Lack of compliance,
  7. Unwillingness to participate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00438503

Locations
Denmark
Holstebro Hospital
Holstebro, Denmark, 7500
Sponsors and Collaborators
Regional Hospital Holstebro
Investigators
Study Chair: Erling B Pedersen, Professor Regional Hospital Holstebro
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00438503     History of Changes
Other Study ID Numbers: MED.RES.2007.02.EBP
Study First Received: February 20, 2007
Last Updated: September 14, 2007
Health Authority: Denmark: Ethics Committee

Keywords provided by Regional Hospital Holstebro:
Hemodialysis, diabetes mellitus,
Chronic renal failure, dialysis ,

Additional relevant MeSH terms:
Diabetic Nephropathies
Kidney Failure, Chronic
Renal Insufficiency
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases

ClinicalTrials.gov processed this record on October 23, 2014